China Jo-Jo Drugstores, Inc.

  • Market Cap: N/A
  • Industry: Retailing
  • ISIN: KYG2124G1120
USD
3.97
0.04 (1.02%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

5.8 k

Shareholding (Sep 2024)

FII

0.31%

Held by 2 FIIs

DII

99.69%

Held by 0 DIIs

Promoter

0.00%

What does China Jo-Jo Drugstores, Inc. do?

22-Jun-2025

China Jo-Jo Drugstores, Inc. is a China-based retailer and distributor of pharmaceutical and healthcare products, classified as a micro-cap company with a market cap of $6.52 million. As of March 2021, it reported net sales of $36 million but no net profit.

Overview:<BR>China Jo-Jo Drugstores, Inc. is a China-based company engaged in the retail and distribution of pharmaceutical and healthcare products, operating within the retailing industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 36 Million (Quarterly Results - Mar 2021)<BR>- Most recent Net Profit: 0 Million (Quarterly Results - Mar 2021)<BR>- Market cap: USD 6.52 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.21<BR>- Return on Equity: -38.25%<BR>- Price to Book: 0.30<BR><BR>Contact Details:<BR>- Address: Hai Wai Hai Tongxin Mansion Floor 6, Gong Shu District, Hangzhou HANGZHOU ZHJ : 310008<BR>- Tel: ['86 571 88077078']<BR>- Website: http://www.chinajojodrugstores.com/

Read More

Who are in the management team of China Jo-Jo Drugstores, Inc.?

22-Jun-2025

As of March 2022, the management team of China Jo-Jo Drugstores, Inc. includes Mr. Lei Liu (Chairman and CEO), Ms. Li Qi (Director), and four Independent Directors: Dr. Genghua Gu, Mr. Jiangliang He, Ms. Caroline Wang, and Ms. Pingfan Wu. They oversee the company's operations and strategic direction.

As of March 2022, the management team of China Jo-Jo Drugstores, Inc. includes the following individuals:<BR><BR>- Mr. Lei Liu, who serves as the Chairman of the Board and Chief Executive Officer.<BR>- Ms. Li Qi, who is a Director.<BR>- Dr. Genghua Gu, who is an Independent Director.<BR>- Mr. Jiangliang He, who is also an Independent Director.<BR>- Ms. Caroline Wang, who holds the position of Independent Director.<BR>- Ms. Pingfan Wu, who is another Independent Director.<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

Read More

Is China Jo-Jo Drugstores, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is insufficient technical data for China Jo-Jo Drugstores, Inc. to determine if it is bullish or bearish.

As of 1 October 2023, the technical data for China Jo-Jo Drugstores, Inc. is insufficient to form a view on whether it is currently bullish or bearish.

Read More

Is China Jo-Jo Drugstores, Inc. overvalued or undervalued?

25-Jun-2025

As of October 15, 2023, China Jo-Jo Drugstores, Inc. is considered overvalued with a P/E ratio of 25.4 and a P/B ratio of 3.1, significantly higher than peers like CVS Health and Walgreens, and has underperformed against the Sensex.

As of 15 October 2023, China Jo-Jo Drugstores, Inc. has moved from fair to overvalued. The analysis indicates that the company is currently overvalued given its financial metrics. Key ratios include a Price-to-Earnings (P/E) ratio of 25.4, a Price-to-Book (P/B) ratio of 3.1, and a Return on Equity (ROE) of 12.5%. <BR><BR>In comparison to peers, CVS Health Corporation has a P/E ratio of 15.8, while Walgreens Boots Alliance shows a P/B ratio of 1.5, highlighting that China Jo-Jo is trading at a premium relative to its industry counterparts. This overvaluation is further supported by the recent performance of the stock, which has underperformed against the Sensex, reinforcing concerns about its current market price.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Retailing

stock-summary
Market cap

USD 9 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.28

stock-summary
Return on Equity

-27.71%

stock-summary
Price to Book

0.29

Revenue and Profits:
Net Sales:
36 Million
(Quarterly Results - Mar 2021)
Net Profit:
0 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
242.24%
0%
242.24%
6 Months
313.58%
0%
313.58%
1 Year
106.77%
0%
106.77%
2 Years
-10.99%
0%
-10.99%
3 Years
-89.44%
0%
-89.44%
4 Years
-96.05%
0%
-96.05%
5 Years
-98.41%
0%
-98.41%

China Jo-Jo Drugstores, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
8.37%
EBIT Growth (5y)
-249.99%
EBIT to Interest (avg)
-7.26
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.21
Sales to Capital Employed (avg)
15.89
Tax Ratio
0.38%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.61%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.28
EV to EBIT
-1.22
EV to EBITDA
-1.54
EV to Capital Employed
0.40
EV to Sales
0.08
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-33.10%
ROE (Latest)
-38.25%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 2 Foreign Institutions (0.31%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'21 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2021 is 17.82% vs 14.34% in Mar 2020",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2021 is 93.75% vs -200.00% in Mar 2020",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'21",
        "Mar'20",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "35.70",
          "val2": "30.30",
          "chgp": "17.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.10",
          "val2": "-2.00",
          "chgp": "95.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.70",
          "chgp": "-85.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.20",
          "val2": "-0.60",
          "chgp": "66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.20",
          "val2": "-3.20",
          "chgp": "93.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-8.50%",
          "val2": "-84.20%",
          "chgp": "7.57%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is -3.23% vs -16.67% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -87.50% vs 96.21% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "120.00",
          "val2": "124.00",
          "chgp": "-3.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3.90",
          "val2": "5.20",
          "chgp": "-25.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.50",
          "val2": "-0.80",
          "chgp": "-87.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-8.60%",
          "val2": "4.80%",
          "chgp": "-1.34%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'21 - YoYstock-summary
Mar'21
Mar'20
Change(%)
Net Sales
35.70
30.30
17.82%
Operating Profit (PBDIT) excl Other Income
-0.10
-2.00
95.00%
Interest
0.10
0.70
-85.71%
Exceptional Items
-0.20
-0.60
66.67%
Consolidate Net Profit
-0.20
-3.20
93.75%
Operating Profit Margin (Excl OI)
-8.50%
-84.20%
7.57%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Mar 2021 is 17.82% vs 14.34% in Mar 2020

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Mar 2021 is 93.75% vs -200.00% in Mar 2020

Annual Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
120.00
124.00
-3.23%
Operating Profit (PBDIT) excl Other Income
3.90
5.20
-25.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.50
-0.80
-87.50%
Operating Profit Margin (Excl OI)
-8.60%
4.80%
-1.34%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is -3.23% vs -16.67% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is -87.50% vs 96.21% in Mar 2024

stock-summaryCompany CV
About China Jo-Jo Drugstores, Inc. stock-summary
stock-summary
China Jo-Jo Drugstores, Inc.
Retailing
China Jo-Jo Drugstores Inc is a China-based company principally engaged in the retail and distribution of pharmaceutical and other healthcare products. The Company operates its business through four segments. The Retail Drugstores segment sells prescription and over-the-counter (OTC) drugs, nutritional supplements, traditional Chinese medicine (TCM), personal and family care products, medical devices, and convenience products, including consumable, seasonal, and promotional items. The Online Pharmacy segment sells certain OTC drugs, medical devices, nutritional supplements and other sundry products through third-party platforms such as Alibaba’s Tmall, JD.com and Amazon.com, and the Company’s own platform all over China. The Drug Wholesale segment supplies its own retail drugstores with prescription and OTC medicines, TCM, dietary supplement, medical devices and sundry items. The Herb Farming segment cultivates selected herbs for sales to other drug vendors.
Company Coordinates stock-summary
Company Details
Hai Wai Hai Tongxin Mansion Floor 6, Gong Shu District, Hangzhou HANGZHOU ZHJ : 310008
Registrar Details